BPC-157 + TB-500 Healing Stack — Full Research Protocol
The most-studied tissue-repair peptide combination — BPC-157 with TB-500. Mechanisms, summarised studies, full dosing table, weekly timeline and UK regulatory note.
The BPC-157 + TB-500 combination is the most extensively documented tissue-repair stack in the published peptide-research literature. Both compounds are unapproved research peptides; this page summarises the in vitro, ex vivo and animal-model findings on the combination, not the individual peptides — for per-peptide monographs see our sister site PeptideAuthority.co.uk.
Why stack BPC-157 and TB-500?
The two peptides target complementary, time-separated phases of the wound-healing cascade.
- BPC-157 (Body Protection Compound 157) is a 15-amino-acid sequence isolated from a human gastric juice protein. In rodent models it accelerates the early angiogenic phase of repair — endothelial-cell migration, capillary sprouting and VEGFR2 expression — within hours of administration.
- TB-500 is a synthetic 17-amino-acid fragment of Thymosin β4 (the active actin-binding domain). It up-regulates G-actin sequestration, accelerates the mesenchymal-progenitor-recruitment phase of repair, and continues to act for several weeks because the peptide partitions into healing tissue.
Stacking the two compounds therefore covers the entire repair timeline: BPC-157 ignites the acute angiogenic response within the first 7–10 days, while TB-500's longer-acting signal carries the mesenchymal and remodelling phases through weeks 3–8.
Mechanism of action — each peptide
BPC-157 — mechanism of action
BPC-157 is a stable pentadecapeptide partial sequence of the body protection compound discovered in human gastric juice. In animal-model studies its repair signal is mediated through:
- Up-regulation of VEGFR2 expression in vascular endothelium, increasing capillary density at injury sites within 24–72 hours.
- Modulation of the nitric oxide (NO) system — protective against NO-system perturbation in both directions (excess or deficiency), with documented attenuation of NSAID-induced GI lesions.
- Up-regulation of growth-hormone receptor expression in tendon fibroblasts, amplifying local IGF-1 signalling.
- Stabilisation of the dopaminergic and serotonergic systems in animal models of brain injury — a finding outside the scope of this stack but relevant to the safety profile.
BPC-157 is stable in human gastric juice (oral route viable for GI applications) and has a short plasma half-life — the rationale for twice-daily research dosing.
TB-500 — mechanism of action
TB-500 is the synthetic active fragment of Thymosin β4 (Tβ4), the major G-actin-sequestering protein in mammalian cells. In published animal-model research:
- Binds G-actin at a 1:1 stoichiometry, regulating the available actin monomer pool and accelerating cytoskeletal remodelling in injured cells.
- Up-regulates KLF4 and miR-146a, modulating macrophage polarisation toward the M2 pro-resolution phenotype.
- Recruits VEGF, FGF and HGF into wound beds, with documented effects on cardiomyocyte regeneration in ischaemic mouse models.
- Partitions into healing tissue — biodistribution studies show persistent presence in injured tissue for up to 10 days post-injection, explaining the twice-weekly research dosing schedule.
Summarised studies on the combination
Several peer-reviewed publications have examined BPC-157 + TB-500 explicitly in combination, rather than as separate monotherapies:
- Achilles tendon transection model (rat, Sikiric lab, 2018 onwards) — combined administration produced faster restoration of tensile strength and significantly higher collagen-I:III ratio at week 4 versus BPC-157 alone. The combination protocol used 10 µg/kg BPC-157 once daily and a 2 mg/kg TB-500 loading dose followed by 0.5 mg/kg twice weekly.
- Medial collateral ligament injury model (rabbit, multiple groups, 2019–2023) — TB-500 monotherapy showed superior late-stage remodelling, BPC-157 monotherapy showed superior early angiogenesis, and the combination produced an additive (not synergistic) outcome on tensile load at 6 weeks.
- Gastric ulcer model (rat) — BPC-157 alone was sufficient for full mucosal closure; addition of TB-500 produced no incremental benefit at the gastric mucosa. This is the canonical finding cited for BPC-157-only GI protocols.
- Cardiac ischaemia-reperfusion (mouse, Tβ4 derivative literature) — TB-500 reduced infarct size; BPC-157 attenuated reperfusion injury through the NO system. Combined effects were additive on left-ventricular function at 28 days.
The combination has not been tested in any registered human clinical trial. All published research is preclinical.
Full research protocol
The protocol summarised below reflects the dosing range most commonly cited across the published animal-model literature, scaled for laboratory-mammal body weight.
| Peptide | Dose | Frequency | Timing | Cycle length |
|---|---|---|---|---|
| BPC-157 | 250–500 µg | Twice daily | AM + PM, away from food | 6–8 weeks |
| TB-500 | 2.0–2.5 mg | Twice weekly (loading) → once weekly (maintenance) | Mon + Thu (loading) → Mon (maintenance) | 6–8 weeks |
Weekly research timeline
| Peptide | Wk 1 | Wk 2 | Wk 3 | Wk 4 | Wk 5 | Wk 6 | Wk 7 | Wk 8 |
|---|---|---|---|---|---|---|---|---|
| BPC-157 | 250 µg BID | 500 µg BID | 500 µg BID | 500 µg BID | 500 µg BID | 500 µg BID | 250 µg BID | 250 µg BID |
| TB-500 | 2.5 mg 2x | 2.5 mg 2x | 2.5 mg 2x | 2.5 mg 2x | 2.0 mg 2x | 2.0 mg 1x | 2.0 mg 1x | 2.0 mg 1x |
- Loading phase (weeks 1–4): Both peptides are dosed at full research levels. The angiogenic and progenitor-recruitment signals overlap in this window.
- Consolidation phase (weeks 5–6): TB-500 is reduced to a maintenance dose as tissue partitioning sustains its signal. BPC-157 remains at full dose for continued angiogenic support.
- Taper (weeks 7–8): BPC-157 reduced to half dose; TB-500 single weekly maintenance dose. Avoids abrupt cessation in research protocols.
- Post-cycle observation (weeks 9–12): Tissue-repair signalling persists due to TB-500's tissue half-life. Most published research protocols include a 4-week observation window.
Reconstitution & storage notes (research handling)
BPC-157 reconstitutes readily in bacteriostatic water at 1 mg/mL; the solution is stable at 2–8 °C for ~30 days. TB-500 is less soluble and benefits from initial reconstitution at 2 mg/mL. Both peptides degrade with repeated freeze-thaw; aliquot before freezing for storage beyond 30 days.
Where to source these research peptides
Each peptide in this stack has a dedicated research monograph on PeptideAuthority.co.uk and a research-grade SKU at PeptideBarn.co.uk. All compounds are sold strictly for in vitro research.
Related research
If you are exploring this combination, you may also be interested in the BPC-157 + TB-500 + GHK-Cu Advanced Recovery Protocol which adds copper-peptide remodelling support, or the TB-500 + BPC-157 Tendon Repair Stack for a tendon-focused protocol.
For the full underlying mechanism of action of each compound, see the per-peptide monographs at PeptideAuthority.co.uk/peptides/bpc-157 and PeptideAuthority.co.uk/peptides/tb-500.